The trajectory of companies tied to flagship drugs like Viagra presents a nuanced investment landscape . While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial profits , the expiry in key territories has introduced substantial uncertainty . Investors are now assessing the consequences of lower-cost